Tower Research Capital (TRC)’s Regencell Bioscience RGC Stock Holding History

Tower Research Capital (TRC)’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25	Buy	+1	New	+$28	﹤0.01%	5055
2025 Q4	–	Sell	-357	Closed	-$5.52K	–	5510
2025 Q3	$5.52K	Buy	+357	New	+$5.12K	﹤0.01%	4230
2025 Q2	–	Sell	-26,524	Closed	-$22.3K	–	5524
2025 Q1	$22.3K	Buy	+26,524	New	+$7.33K	﹤0.01%	2860
2023 Q4	–	Sell	-3,230	Closed	-$1.19K	–	6136
2023 Q3	$1.19K	Buy	+3,230	New	+$1.34K	﹤0.01%	5385
2023 Q2	–	Sell	-7,600	Closed	-$5K	–	6314
2023 Q1	$5K	Buy	+7,600	New	+$5.6K	﹤0.01%	4988
2022 Q4	–	Sell	-14,136	Closed	-$12K	–	6287
2022 Q3	$12K	Sell	14,136 -7,828	-36%	-$6.85K	﹤0.01%	4365
2022 Q2	$20K	Buy	21,964 +5,548	+34%	+$4.18K	﹤0.01%	3802
2022 Q1	$10K	Buy	+16,416	New	+$14.1K	﹤0.01%	4335
2021 Q4	–	Sell	-124,260	Closed	-$74K	–	6501
2021 Q3	$74K	Buy	+124,260	New	+$56.1K	﹤0.01%	2661

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Tower Research Capital (TRC)'s RGC Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Regencell Bioscience (RGC) in Q1 2026: 1 share worth $25. The stake represents ﹤0.01% of the portfolio and ranks #5055 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in RGC as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in RGC in Q3 2021 and has held it in 9 quarters since. The position peaked at $74K in Q3 2021. 31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

Tower Research Capital (TRC) held 1 share of Regencell Bioscience worth $25 as of Q1 2026.
Regencell Bioscience was a new Tower Research Capital (TRC) position in Q1 2026.
Regencell Bioscience made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #5055 holding.
Tower Research Capital (TRC) first reported a position in Regencell Bioscience in Q3 2021 and has held it in 9 quarters since.
Tower Research Capital (TRC)'s Regencell Bioscience position peaked at $74K in Q3 2021.
31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.